SILICON LABORATORIES INC Form 10-Q October 24, 2012 Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q



x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 29, 2012

or

" TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-29823

SILICON LABORATORIES INC.

(Exact name of registrant as specified in its charter)

Delaware	74-2793174
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

400 West Cesar Chavez, Austin, Texas (Address of principal executive offices)

78701 (Zip Code)

(512) 416-8500

(Registrant s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer x Accelerated filer "

Non-accelerated filer " Smaller reporting company "

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). "Yes x No

As of October 17, 2012, 41,599,066 shares of common stock of Silicon Laboratories Inc. were outstanding.

Table of Contents

Table of Contents

Part I.	Financial Information	o <u>n</u>		Page Number
		Item 1.	Financial Statements (Unaudited):	
			Condensed Consolidated Balance Sheets at September 29, 2012 and December 31, 2011	3
			Condensed Consolidated Statements of Income for the three and nine months ended September 29, 2012 and October 1, 2011	4
			Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 29, 2012 and October 1, 2011	5
			Condensed Consolidated Statements of Cash Flows for the nine months ended September 29, 2012 and October 1, 2011	6
			Notes to Condensed Consolidated Financial Statements	7
		Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	s 24
		Item 3.	Quantitative and Qualitative Disclosures About Market Risk	35
		Item 4.	Controls and Procedures	35
Part II.	Other Information			
		Item 1.	<u>Legal Proceedings</u>	36
		Item 1A.	Risk Factors	36
		Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	51
		Item 3.	<u>Defaults Upon Senior Securities</u>	51
		Item 4.	Mine Safety Disclosures	51
		Item 5.	Other Information	51
		Item 6.	<u>Exhibits</u>	51

Cautionary Statement

Except for the historical financial information contained herein, the matters discussed in this report on Form 10-Q (as well as documents incorporated herein by reference) may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include declarations regarding the intent, belief or current expectations of Silicon Laboratories Inc. and its management and may be signified by the words

believe, estimate, expect, intend, anticipate, plan, project, will or similar language. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties. Actual results could differ materially from those indicated by such forward-looking statements. Factors that could cause or contribute to such differences include those discussed under Risk Factors and elsewhere in this report. Silicon Laboratories disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

2

Table of Contents

Part I. Financial Information

Item 1. Financial Statements

Silicon Laboratories Inc.

Condensed Consolidated Balance Sheets

(In thousands, except per share data)

(Unaudited)

	September 29,	December 31,
	2012	2011
Assets		
Current assets:		
Cash and cash equivalents	\$ 125,505	\$ 94,964
Short-term investments	148,573	212,526
Accounts receivable, net of allowances for doubtful accounts of \$789 at September 29, 2012		
and \$725 at December 31, 2011	75,749	55,351
Inventories	42,523	34,778
Deferred income taxes	15,870	11,563
Prepaid expenses and other current assets	36,735	43,867
Total current assets	444,955	453,049
Long-term investments	11,418	17,477
Property and equipment, net	136,321	25,141
Goodwill	130,069	115,489
Other intangible assets, net	94,611	60,005
Other assets, net	37,669	34,830
Total assets	\$ 855,043	\$ 705,991
Liabilities and Stockholders Equity		
Current liabilities:		
Accounts payable	\$ 35,476	\$ 26,354
Current portion of long-term debt	5,000	
Accrued expenses	41,441	30,857
Deferred income on shipments to distributors	30,903	24,962
Income taxes	3,339	665
Total current liabilities	116,159	82,838
Long-term debt	95,000	
Other non-current liabilities	22,663	24,214
Total liabilities	233,822	107,052
Commitments and contingencies		
Stockholders equity:		
Preferred stock \$0.0001 par value; 10,000 shares authorized; no shares issued and outstanding		
Common stock \$0.0001 par value; 250,000 shares authorized; 41,706 and 42,068 shares		
issued and outstanding at September 29, 2012 and December 31, 2011, respectively	4	4
Additional paid-in capital	4	14,749
Auditional paid-ill capital		14,749

Retained earnings	622,)98	586,653
Accumulated other comprehensive loss	(881)	(2,467)
Total stockholders equity	621,	221	598,939
Total liabilities and stockholders equity	\$ 855,	043 \$	705,991

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

Table of Contents

Silicon Laboratories Inc.

Condensed Consolidated Statements of Income

(In thousands, except per share data)

(Unaudited)

		Three Months Ended			Nine Months Ended				
	Sep	September 29,		October 1,		September 29,		October 1,	
		2012		2011		2012		2011	
Revenues	\$	149,461	\$	119,100	\$	410,833	\$	364,933	
Cost of revenues		62,968		46,203		166,442		143,666	
Gross margin		86,493		72,897		244,391			